Arthneeti

Johnson & Johnson Q2 FY26 Results — Earnings Call Analysis

Published 29 May 2026 | Pharmaceuticals | Market Cap: ₹5.6L Cr

- Johnson & Johnson expects double-digit top-line growth by the end of the decade, supported by strong momentum starting in 2026 with operational sales growth of 6.4% in Q1. - Johnson & Johnson expects double-digit revenue growth by the end of the decade, driven by a strong portfolio and pipeline.

From Johnson & Johnson's Q2 FY26 earnings-call transcript · updated 29 May 2026.

Price

₹230.8

Market Cap

₹5.6L Cr

P/E Ratio

26.7

Revenue Rank

Rank 3

Margin Rank

Rank 4

How does Johnson & Johnson rank in Pharmaceuticals?

Compare Johnson & Johnson against every Pharmaceuticals company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 3Margin: Rank 4
View Pharmaceuticals leaderboard →

📊 Revenue & Sales Performance

Rank 3
  • →Johnson & Johnson expects double-digit top-line growth by the end of the decade, supported by strong momentum starting in 2026 with operational sales growth of 6.4% in Q1.
  • →Innovative Medicine showing robust growth with 7.4% operational sales increase driven by oncology, immunology, and neuroscience; 10 brands growing double digits.
  • →Key growth drivers include new product launches such as ICOTYDE, TREMFYA, RYBREVANT, and INLEXZO, with ICOTYDE projected to be one of the largest products ever.
  • →MedTech anticipates high single-digit growth contribution, with cardiovascular business growing rapidly due to acquisitions (Abiomed and Shockwave) and new technologies like Impella and IVL.
  • →Continued expansion globally, increased market share, and new FDA approvals support sustained volume growth.
  • →Strong pipeline and ongoing clinical trials to further expand indications and market reach.
  • →Investments in innovation and manufacturing bolster future capacity and growth potential.

📈 Profitability & Margins

Rank 4
  • →Johnson & Johnson expects double-digit revenue growth by the end of the decade, driven by a strong portfolio and pipeline.
  • →For 2026, operational sales growth guidance is raised to 5.9%-6.9%, with a midpoint of $100.2 billion (6.4%).
  • →Reported sales growth guidance is 6.5%-7.5%, midpoint $100.8 billion (7%).
  • →Adjusted pretax operating margin is expected to improve by at least 50 basis points in 2026.
  • →Adjusted operational earnings per share guidance is raised to $11.30-$11.50 (5.7% growth at midpoint); reported adjusted EPS expected at $11.55 (7.1% growth).
  • →Cost pressures and investments will be partly offset by operating leverage and revenue growth.
  • →New product launches, especially ICOTYDE, RYBREVANT, INLEXZO, and MedTech innovations, underpin confidence in margin expansion and earnings growth.
  • →Business development remains opportunistic but not central to growth expectations.

🏗️ Capital Expenditure Plans

Yes
  • →Johnson & Johnson plans to invest $55 billion in U.S.-based manufacturing technology and R&D through early 2029.
  • →By the end of 2025, approximately $12 billion (22% of the $55 billion) had already been invested.
  • →Significant manufacturing investments are underway in North Carolina and Pennsylvania, with more announcements expected in upcoming quarters.
  • →The company emphasizes ongoing investment in innovation, including heavier investment in new product launches and pipeline strengthening in the first half of 2026.
  • →Capital expenditures are increasing, especially in U.S. rebate programs and manufacturing, but these were anticipated and aligned with the company’s strategic growth initiatives.
  • →Investment in MedTech includes advancing cardiovascular and robotic surgery technologies (OTTAVA system), with expected product launches in 2026.

💰 Fundraising & Capital Structure

No information
  • →As of Q1 2026, Johnson & Johnson ended the quarter with approximately $22 billion in cash and marketable securities and $55 billion in debt, resulting in net debt of about $33 billion.
  • →Free cash flow in Q1 was approximately $1.5 billion, which is below the full-year projection due to timing.
  • →The company maintains a strong financial position and cash flow generation, providing a competitive advantage for capital allocation and innovation investment.
  • →There is no explicit mention in the provided pages of planned or upcoming fundraising through debt or equity.
  • →The company continues to invest heavily in manufacturing and R&D, with $12 billion invested through 2025 toward a $55 billion target by early 2029.
  • →The approach to capital allocation remains consistent, focusing on innovation and opportunistic business development without dependence on M&A for growth.

📋 Order Book & Pipeline

No information
The provided pages do not explicitly mention current or expected orderbook or pending orders in quantified terms. However, relevant information on sales momentum and demand includes: - Vision business showed solid sales growth of 3.6% with expected acceleration through the year. - Surgical Vision grew 6%, with growth offset by competitive pressures in the U.S. but expected to accelerate in the second half of the year. - Contact lens sales rose 2.7%, driven by strong product families. - MedTech showed strong adoption of new products, including Impella devices (14% growth) and Shockwave (18.1% growth), with continued expansion globally and competitive market entrance. - Overall company sales growth guidance for 2026 raised to a midpoint of $100.2 billion (6.4% operational growth). - Strong momentum overall with expectation of accelerating growth supported by multiple new product launches and pipeline strength. No direct figures on orderbook or pending orders were disclosed in these excerpts.

Key Metrics

Revenue

Rank 3

Margin

Rank 4

Capex

Yes

Fundraise

No information

Order Book

No information

Continue your research

Others in Pharmaceuticals this season

  • Elanco Animal Health Incorporated (Q2 FY26)

    Elanco Animal Health Incorporated Q2 FY26 quarterly results analysis. Elanco expects continued momentum with high single-digit to low double-digit growth in U.S

  • Axsome Therapeutics, Inc. (Q2 FY26)

    Axsome Therapeutics, Inc. Q2 FY26 quarterly results analysis. AUVELITY peak sales updated to at least $8 billion annually, with roughly equal contributions from

  • Jazz Pharmaceuticals plc (Q2 FY26)

    Jazz Pharmaceuticals plc Q2 FY26 quarterly results analysis. Epidiolex: Encouraged by strong first-quarter performance ($250 million; 15% revenue growth, 16% vo

  • Viatris Inc. (Q2 FY26)

    Viatris Inc. Q2 FY26 quarterly results analysis. Viatris aims for 4% organic revenue growth by 2030, starting strong with 3% growth in Q1 2026. Market Cap $18,7

Compare:vs AstraZeneca PLCvs Novartis AGvs Novo Nordisk A/S

Frequently Asked Questions

What were Johnson & Johnson Q2 FY26 results?

- Johnson & Johnson expects double-digit top-line growth by the end of the decade, supported by strong momentum starting in 2026 with operational sales growth of 6.4% in Q1. - Johnson & Johnson expects double-digit revenue growth by the end of the decade, driven by a strong portfolio and pipeline.

What is Johnson & Johnson share price analysis?

Johnson & Johnson currently shows a below-average growth signal. The stock trades at a P/E of 26.7 with a market cap of $555,586. Investors should review the full earnings analysis for detailed insights.

Is Johnson & Johnson planning capital expenditure?

- Johnson & Johnson plans to invest $55 billion in U.S.-based manufacturing technology and R&D through early 2029.

Keep Johnson & Johnson on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.